FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313447346> ?p ?o ?g. }

• W4313447346 endingPage "117" @default.
• W4313447346 startingPage "109" @default.
• W4313447346 abstract "The endometrial cancer molecular classification has been integrated into the 2020 World Health Organization (WHO) diagnostic classification and European treatment guidelines, and provides direction towards more effective and less toxic adjuvant treatment strategies for women with endometrial cancer.The RAINBO program of clinical trials will investigate four molecular class-directed adjuvant treatment strategies following surgical resection to either increase cure rates through the addition of novel targeted therapies or safely reduce toxicity and improve quality of life through treatment de-escalation.Molecular-directed adjuvant treatment strategies will improve clinical outcomes and reduce toxicity of unwarranted therapies in women with endometrial cancer. The overarching and translational research RAINBO program will advance knowledge of predictive and prognostic (bio)markers that will improve prognostication and treatment allocation.The RAINBO program is a platform of four international clinical trials and an overarching research program. The randomized phase III p53abn-RED trial for women with invasive stage I-III p53abn endometrial cancer compares adjuvant chemoradiation followed by olaparib for 2 years with adjuvant chemoradiation alone. The randomized phase III MMRd-GREEN trial for women with stage II (with lymphovascular space invasion (LVSI)) or stage III mismatch repair-deficient (MMRd) endometrial cancer compares adjuvant radiotherapy with concurrent and adjuvant durvalumab for 1 year to radiotherapy alone. The randomized phase III NSMP-ORANGE trial is a treatment de-escalation trial for women with estrogen receptor positive stage II (with LVSI) or stage III no specific molecular profile (NSMP) endometrial cancer comparing radiotherapy followed by progestin for 2 years to adjuvant chemoradiation. The POLEmut-BLUE trial is a phase II trial in which the safety of de-escalation of adjuvant therapy is investigated for women with stage I-III POLEmut endometrial cancer: no adjuvant therapy for lower-risk disease and no adjuvant therapy or radiotherapy alone for higher-risk disease. The overarching RAINBO program will combine data and tumor material of all participants to perform translational research and evaluate molecular class-based adjuvant therapy in terms of efficacy, toxicity, quality of life, and cost-utility.Inclusion criteria include a histologically confirmed diagnosis of endometrial cancer treated by hysterectomy and bilateral salpingo-oophorectomy with or without lymphadenectomy or sentinel lymph node biopsy, with no macroscopic residual disease after surgery and no distant metastases, and molecular classification according to the WHO 2020 algorithm.Recurrence-free survival at 3 years in the p53abn-RED, MMRd-GREEN, and NSMP-ORANGE trials and pelvic recurrence at 3 years in the POLEmut-BLUE trial.The p53abn-RED trial will include 554 patients, the MMRd-GREEN trial 316, the NSMP-ORANGE trial 600, and the POLEmut-BLUE trial 145 (120 for lower-risk disease and approximately 25 for higher-risk disease). The overarching research program will pool the four sub-trials resulting in a total sample size of around 1600.The four clinical trials will have different completion dates; main results are expected from 2028.The RAINBO program is registered at clinicaltrials.gov (NCT05255653)." @default.
• W4313447346 created "2023-01-06" @default.
• W4313447346 date "2022-12-20" @default.
• W4313447346 modified "2023-10-13" @default.
• W4313447346 title "Refining adjuvant treatment in endometrial cancer based on molecular features: the RAINBO clinical trial program" @default.
• W4313447346 cites W1519719924 @default.
• W4313447346 cites W1994826332 @default.
• W4313447346 cites W2022495797 @default.
• W4313447346 cites W2120897875 @default.
• W4313447346 cites W2468311487 @default.
• W4313447346 cites W2733813554 @default.
• W4313447346 cites W2789454469 @default.
• W4313447346 cites W2900109386 @default.
• W4313447346 cites W2996314623 @default.
• W4313447346 cites W3047152751 @default.
• W4313447346 cites W3097490979 @default.
• W4313447346 cites W3114074286 @default.
• W4313447346 cites W3145769307 @default.
• W4313447346 cites W3167167915 @default.
• W4313447346 cites W4220818710 @default.
• W4313447346 cites W4226278337 @default.
• W4313447346 doi "https://doi.org/10.1136/ijgc-2022-004039" @default.
• W4313447346 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36600534" @default.
• W4313447346 hasPublicationYear "2022" @default.
• W4313447346 type Work @default.
• W4313447346 citedByCount "19" @default.
• W4313447346 countsByYear W43134473462023 @default.
• W4313447346 crossrefType "journal-article" @default.
• W4313447346 hasBestOaLocation W43134473461 @default.
• W4313447346 hasConcept C121608353 @default.
• W4313447346 hasConcept C126322002 @default.
• W4313447346 hasConcept C143998085 @default.
• W4313447346 hasConcept C146357865 @default.
• W4313447346 hasConcept C151730666 @default.
• W4313447346 hasConcept C168563851 @default.
• W4313447346 hasConcept C2777088508 @default.
• W4313447346 hasConcept C2777863537 @default.
• W4313447346 hasConcept C29456083 @default.
• W4313447346 hasConcept C509974204 @default.
• W4313447346 hasConcept C535046627 @default.
• W4313447346 hasConcept C71924100 @default.
• W4313447346 hasConcept C86803240 @default.
• W4313447346 hasConceptScore W4313447346C121608353 @default.
• W4313447346 hasConceptScore W4313447346C126322002 @default.
• W4313447346 hasConceptScore W4313447346C143998085 @default.
• W4313447346 hasConceptScore W4313447346C146357865 @default.
• W4313447346 hasConceptScore W4313447346C151730666 @default.
• W4313447346 hasConceptScore W4313447346C168563851 @default.
• W4313447346 hasConceptScore W4313447346C2777088508 @default.
• W4313447346 hasConceptScore W4313447346C2777863537 @default.
• W4313447346 hasConceptScore W4313447346C29456083 @default.
• W4313447346 hasConceptScore W4313447346C509974204 @default.
• W4313447346 hasConceptScore W4313447346C535046627 @default.
• W4313447346 hasConceptScore W4313447346C71924100 @default.
• W4313447346 hasConceptScore W4313447346C86803240 @default.
• W4313447346 hasFunder F4320307770 @default.
• W4313447346 hasFunder F4320322777 @default.
• W4313447346 hasFunder F4320334506 @default.
• W4313447346 hasIssue "1" @default.
• W4313447346 hasLocation W43134473461 @default.
• W4313447346 hasLocation W43134473462 @default.
• W4313447346 hasLocation W43134473463 @default.
• W4313447346 hasLocation W43134473464 @default.
• W4313447346 hasOpenAccess W4313447346 @default.
• W4313447346 hasPrimaryLocation W43134473461 @default.
• W4313447346 hasRelatedWork W1980543189 @default.
• W4313447346 hasRelatedWork W2032997711 @default.
• W4313447346 hasRelatedWork W2070968338 @default.
• W4313447346 hasRelatedWork W2090917545 @default.
• W4313447346 hasRelatedWork W2159649569 @default.
• W4313447346 hasRelatedWork W2320082465 @default.
• W4313447346 hasRelatedWork W2913236424 @default.
• W4313447346 hasRelatedWork W2972705194 @default.
• W4313447346 hasRelatedWork W4252324012 @default.
• W4313447346 hasRelatedWork W4361970035 @default.
• W4313447346 hasVolume "33" @default.
• W4313447346 isParatext "false" @default.
• W4313447346 isRetracted "false" @default.
• W4313447346 workType "article" @default.